News
Watch: What’s New in Myeloma Treatment: a New Zealand PerspectiveÂ
What’s New in Myeloma Treatment: a New Zealand Perspective Dr. Leanne Berkahn, Dr. Henry Chan, Dr. Phillip Insull, and Dr. David Simpson, spoke at...
Watch: Improving Survival in Multiple Myeloma
Improving Survival in Multiple Myeloma Dr. Henry Chan from North Shore Hospital spoke at our patient seminar on his recent work looking at multiple...
Cancer Society calls for major changes to save lives
The Cancer Society is calling for major changes to cancer services to save lives. It says 2,500 more New Zealanders would have survived cancer if...
Newsletter: February 2018
Happy New Year & greetings to you all Patient seminars: save the date Auckland on 28 February at North Shore Hospital Auditorium Wellington on 8...
You’re invited to a patient seminar – Wellington
INVITATION Patient Seminar: CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Presented by Dr Rob Weinkove on 8 March, 5.30-7pm at...
You’re invited to a patient seminar – Auckland
INVITATION Patient Seminar: What's New in Myeloma Treatment: a New Zealand Perspective with...
Multinational Clinical Study
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory...
Tell us how we can help
We're keen to know how Myeloma New Zealand can help you. What you'd like to hear about on the website? What support you feel would be useful? We'd...
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according...
You’re invited to a patient seminar
INVITATION Patient Seminar:  Improving Survival in Multiple Myeloma Dr. Henry Chan from North Shore Hospital will be speaking at our patient seminar...
Daratumumab approved for use on NHS in Scotland
Patients in Scotland will now be able to access the new myeloma treatment, daratumumab (Darzalex®) on the NHS, after the Scottish Medicines...
Article of the Week: Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
For this week's Article of the Week, we look at an article that describes a review of patient data from the Mayo Clinic. The study sought to...